Catalyst Pharmaceuticals, Inc. (CPRX)
Stock Price:
$3.70 USD
0.21 (6.02%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
383.50M |
| Revenue (ttm) |
118.18M |
| Net Income (ttm) |
71.48M |
| Shares Out |
103.65M |
| EPS (ttm) |
0.67 |
| PE Ratio |
5.52 |
| Forward PE |
8.73 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$3.70 |
| Previous Close |
$3.49 |
| Change ($) |
0.21 |
| Change (%) |
6.02% |
| Day's Open |
3.53 |
| Day's Range |
3.51 - 3.72 |
| Day's Volume |
1,174,728 |
| 52-Week Range |
2.55 - 5.28 |
More Stats
| Market Cap |
383.50M |
| Enterprise Value |
256.38M |
| Earnings Date (est) |
Mar 17, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
103.65M |
| Float |
96.48M |
| EPS (basic) |
0.69 |
| EPS (diluted) |
0.67 |
| FCF / Share |
0.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
18.11% |
| FCF Yield |
11.53% |
| Payout Ratio |
n/a |
| Shares Short |
13.44M |
| Short Ratio |
10.87 |
| Short % of Float |
13.93% |
| Beta |
1.54 |
| PE Ratio |
5.52 |
| Forward PE |
8.73 |
| P/FCF Ratio |
8.67 |
| PS Ratio |
3.25 |
| PB Ratio |
2.31 |
| Revenue |
118.18M |
| Operating Income |
40.69M |
| Net Income |
71.48M |
| Free Cash Flow |
44.21M |
| Net Cash |
127.12M |
| Net Cash / Share |
1.23 |
| Gross Margin |
74.08% |
| Operating Margin |
34.43% |
| Profit Margin |
60.50% |
| FCF Margin |
37.41% |
| ROA |
18.73% |
| ROE |
60.93% |
| ROIC |
487.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.40*
(100.00% upside)
Low
5.50
Current: $3.70
High
9.00
Target: 7.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 102 | 0.50 | - | - | - | - | - | - | - | - |
| Revenue Growth | 20361.27% | - | - | - | - | - | - | - | - | - |
| Gross Profit | 87.55 | 0.50 | - | - | - | - | - | - | - | - |
| Operating Income | 31.82 | -35.30 | -18.68 | -19.28 | -20.40 | -14.59 | -10.31 | -5.22 | -6.08 | -4.51 |
| Net Income | 31.88 | -34.00 | -18.41 | -18.07 | -20.23 | -15.51 | -12.15 | -4.08 | -6.39 | -4.01 |
| Shares Outstanding | 103 | 103 | 85.80 | 82.88 | 80.86 | 64.14 | 45.45 | 30.03 | 21.73 | 18.58 |
| Earnings Per Share | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 |
| Operating Cash Flow | 34.61 | -26.15 | -13.74 | -17.96 | -18.02 | -12.94 | -9.88 | -5.14 | -4.99 | -3.76 |
| Capital Expenditures | -0.02 | -0.09 | - | -0.10 | -0.02 | -0.06 | -0.01 | -0.05 | - | - |
| Free Cash Flow | 34.59 | -26.24 | -13.74 | -18.06 | -18.04 | -13.00 | -9.89 | -5.19 | -4.99 | -3.76 |
| Cash & Equivalents | 94.53 | 53.49 | 84.02 | 40.41 | 58.41 | 39.28 | 23.72 | 15.43 | 6.04 | 5.49 |
| Total Debt | 0.65 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 93.88 | 53.49 | 84.02 | 40.41 | 58.41 | 39.28 | 23.72 | 15.43 | 6.04 | 5.49 |
| Assets | 112 | 60.45 | 85.39 | 41.71 | 60.10 | 43.91 | 25.37 | 16.79 | 6.25 | 5.83 |
| Liabilities | 24.75 | 9.67 | 4.42 | 2.40 | 4.63 | 8.67 | 3.98 | 2.17 | 2.49 | 0.31 |
| Book Value | 87.63 | 50.78 | 80.96 | 39.31 | 55.48 | 35.24 | 21.39 | 14.62 | 3.76 | 5.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Catalyst Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
76 |
| CEO |
Patrick J. McEnany |
Stock Information
| Ticker Symbol |
CPRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CPRX |
| IPO Date |
November 8, 2006 |
Description
Catalyst Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.